NASDAQ:MOLN Molecular Partners (MOLN) Stock Price, News & Analysis $2.53 -0.13 (-4.89%) Closing price 03:58 PM EasternExtended Trading$2.53 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Molecular Partners Stock (NASDAQ:MOLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Molecular Partners alerts:Sign Up Key Stats Today's Range$2.52▼$2.5350-Day Range$2.56▼$4.3052-Week Range$2.52▼$5.36Volume928 shsAverage Volume4,155 shsMarket Capitalization$102.16 millionP/E RatioN/ADividend YieldN/APrice Target$8.38Consensus RatingHold Company Overview Molecular Partners is a Swiss biotechnology company that develops protein-based medicines using its proprietary DARPin platform. Designed ankyrin repeat proteins, or DARPins, are engineered to bind specific biological targets and can be developed to act on one or several targets. The company’s research focuses on therapeutic candidates for cancer and other serious diseases. Its pipeline has included treatments designed to engage immune cells against tumors and to target proteins found in the tumor environment. Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners is headquartered in Schlieren, Switzerland. Co-founder Patrick Amstutz has served as its chief executive officer, and the company has pursued research and development through its own programs and collaborations with other biotechnology and pharmaceutical companies.AI Generated. May Contain Errors. Read More Molecular Partners Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreMOLN MarketRank™: 2.85127362366 of 5 starsMolecular Partners scored higher than 57% of companies evaluated by MarketBeat, and ranked 489th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingMolecular Partners has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMolecular Partners has a consensus price target of $8.38, representing about 230.9% upside from its current price of $2.53.Amount of Analyst CoverageMolecular Partners has only been the subject of 2 research reports in the past 90 days.Read more about Molecular Partners' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Molecular Partners are expected to grow in the coming year, from ($1.22) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Partners is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Partners is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Partners has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Molecular Partners has been sold short.Short Interest Ratio / Days to CoverMolecular Partners has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Molecular Partners has recently decreased by 99.83%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMolecular Partners does not currently pay a dividend.Dividend GrowthMolecular Partners does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Molecular Partners insiders have not sold or bought any company stock.Percentage Held by Insiders5.93% of the stock of Molecular Partners is held by insiders.Percentage Held by Institutions26.55% of the stock of Molecular Partners is held by institutions.Read more about Molecular Partners' insider trading history. Receive MOLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MOLN Stock News HeadlinesMolecular Partners to Present at Inaugural UBS Global Biopharma ConferenceNovember 13, 2026 | globenewswire.comMolecular Partners Presents New Preclinical Data for Next-Generation T Cell Engager MP0632 at SITC 2026November 6, 2026 | globenewswire.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 20 at 1:00 AM | Porter & Company (Ad)Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026November 5, 2026 | globenewswire.comSwiss biotech firm Molecular Partners to cut nearly half of workforceOctober 29, 2026 | msn.comMolecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted RadiotherapyOctober 29, 2026 | globenewswire.comMolecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70October 22, 2026 | markets.businessinsider.comMolecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash BaseAugust 26, 2026 | theglobeandmail.comSee More Headlines MOLN Stock Analysis - Frequently Asked Questions How have MOLN shares performed this year? Molecular Partners' stock was trading at $4.4450 on January 1st, 2026. Since then, MOLN shares have decreased by 43.1% and is now trading at $2.5310. How were Molecular Partners' earnings last quarter? Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) issued its quarterly earnings data on Thursday, October, 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.08. When did Molecular Partners IPO? Molecular Partners (MOLN) raised $64 million in an initial public offering (IPO) on the week of June 14th 2021. The company issued 3,000,000 shares at $21.25 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets served as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of Molecular Partners? Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Molecular Partners own? Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include Agenus (AGEN), Altimmune (ALT), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunityBio (IBRX), NVIDIA (NVDA) and Sangamo Therapeutics (SGMO). Company Calendar Last Earnings10/29/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (26m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MOLN's financial health is in the Red zone, according to TradeSmith. MOLN has been in this zone for over 26 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MOLN CIK1745114 Webwww.molecularpartners.com Phone41-44-755-7700FaxN/AEmployees134Year Founded2004Price Target and Rating Average Price Target for Molecular Partners$8.38 High Price Target$13.00 Low Price Target$3.75 Potential Upside/Downside+231.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-80.03% Return on Assets-62.56% Debt Debt-to-Equity RatioN/A Current Ratio6.46 Quick Ratio6.46 Sales & Book Value Annual Sales$5.65 million Price / Sales18.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book1.64Miscellaneous Outstanding Shares40,380,000Free Float37,981,000Market Cap$102.16 million OptionableNot Optionable Beta1.17 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:MOLN) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBlack Friday Special: Buy These Stocks Before Nov. 30thKeith Kaplan's firm has invested $17 million in its own AI research and tools, and 180,000 people worldwide no...TradeSmith | SponsoredWashington's deadline. Elon's problem.On January 1, 2027, Washington raises the outside-China sourcing requirement for grid battery projects seeking...Behind the Markets | SponsoredThe One-Ticker Retirement BoostA $10,000 investment at its 1998 start would be worth over $630,000 today, roughly 6X the S&P 500 over the sam...The Oxford Club | SponsoredShould I sell? $84 off ends Dec 9A stock you own drops 20%, and you're asking yourself: should I sell? Seeking Alpha Premium gives you a second...Seeking Alpha | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.